8-K/A: Aditxt Amends Merger Agreement with Evofem, Provides Financial Update

Aditxt amends its merger agreement with Evofem, extending the consummation date and providing additional investment, while Evofem reports Q1 2025 financial results.

Summary

• Aditxt and Evofem have amended their merger agreement, extending the consummation date to September 30, 2025.
• Aditxt will make an additional $1.5 million investment in Evofem by April 7, 2025.
• Evofem's Q1 2025 net product sales were $845,000, a decrease from $3.603 million in Q1 2024.
• Evofem's research and development expenses showed a benefit of $5.035 million in Q1 2025 due to negotiated trade payables, compared to expenses of $594,000 in Q1 2024.
• Evofem's Q1 2025 net loss attributable to common stockholders was $953,000, or $0.01 per share, compared to a net loss of $4.856 million, or $0.16 per share, in Q1 2024.
• Evofem's cash and cash equivalents, including restricted cash, totaled $1.109 million as of March 31, 2025.
• Evofem has a working capital deficit of $65.0 million and an accumulated deficit of $896.7 million as of March 31, 2025.
• Evofem's management believes current cash and cash equivalents are insufficient to fund operations for the next 12 months.
• Evofem is pursuing strategies to meet cash flow needs, including revenue generation, payables restructuring, and additional funding through various means.
• There is substantial doubt about Evofem's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with some positive developments (amended merger agreement, SOLOSEC acquisition) offset by significant financial challenges (revenue decline, going concern uncertainty). The overall sentiment is negative due to the company's precarious financial situation.

Positives

• Evofem negotiated a portion of its trade payables, resulting in a $5.6 million reduction in research and development expenses.
• Evofem is actively pursuing strategies to improve its financial position, including revenue generation and payables restructuring.
• Evofem has secured a licensing agreement with Pharma 1 for commercial rights to PHEXXI in the Middle East.
• Evofem has re-launched SOLOSEC in November 2024, leveraging its commercial infrastructure and physician relationships.

Negatives

• Evofem's Q1 2025 net product sales decreased significantly compared to Q1 2024.
• Evofem has a substantial working capital deficit and accumulated deficit.
• Evofem's management believes current cash and cash equivalents are insufficient to fund operations for the next 12 months.
• There is substantial doubt about Evofem's ability to continue as a going concern.
• Evofem is contesting a Notice of Event of Default from Future Pak, LLC.

Risks

• Any disruptions in the commercialization of PHEXXI or SOLOSEC and/or the products supply chains could have a material adverse effect on the Company's business, results of operations and financial condition.
• Evofem's ability to obtain additional funding through various means is uncertain.
• Failure to raise additional funding and implement its strategic development plan could force Evofem to make further reductions in spending or cease operations entirely.
• The company is contesting a Notice of Event of Default and Reservation of Rights from Future Pak, LLC.
• The company's common stock was removed from OTCQB and began trading on the OTC Pink Current (OTCPK) at market open on April 23, 2025.

Future Outlook

Evofem will continue to focus on top-line growth while maintaining a lean operating structure and explore opportunities for organic growth, entry into new markets, and potential expansion of its product offerings beyond PHEXXI and SOLOSEC.

Management Comments

• Management believes that the Company's cash and cash equivalents as of March 31, 2025 are insufficient to fund operations for at least the next 12 months from the date on which this Quarterly Report on Form 10-Q is filed with the SEC.

Industry Context

The announcement reflects the challenges faced by smaller biopharmaceutical companies in achieving profitability and securing funding, particularly in the competitive women's health market. The merger with Aditxt is aimed at providing Evofem with the necessary capital and resources to continue commercializing its products.

Comparison to Industry Standards

• It is difficult to compare Evofem's results directly to industry standards due to its unique product portfolio and focus on non-hormonal contraception.
• However, the company's revenue decline and going concern uncertainty are concerning compared to larger, more established pharmaceutical companies.
• Companies like Organon & Co. (women's health) and Teva Pharmaceutical Industries Ltd. (generic pharmaceuticals) are much larger and have more diversified revenue streams.
• Evofem's reliance on PHEXXI and SOLOSEC makes it more vulnerable to market fluctuations and competition.

Legal Proceedings

• Evofem is working with TherapeuticsMD on resolution of a trademark dispute.
• Evofem has received letters from purported Company stockholders demanding that the Company's board of directors take action on behalf of the Company to remedy allegations regarding the Company's disclosures to shareholders with respect to various alleged omissions of material information in its preliminary proxy statement filed September 23, 2024 relating to the A&R Merger Agreement.
• Evofem is contesting a Notice of Event of Default and Reservation of Rights from Future Pak, LLC.

Related Party Transactions

• On March 20, 2025, Windtree Therapeutics, Inc. (Windtree) and the Company entered into a License and Supply Agreement, as amended on March 28, 2025 (collectively, the Windtree License and Supply Agreement), wherein Windtree agreed to become a manufacturer and supplier of PHEXXI.
• Aditxt and Evofem entered into a securities purchase agreement whereby Evofem issued senior subordinated convertible notes to Aditxt in an aggregate principal amount of $2,300 and warrants to purchase up to 149,850,150 shares of Evofem common stock with an exercise price of $0.0154 for net proceeds to Evofem of $1,500 in satisfaction of the Fifth Parent Investment.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential for liquidation.
• Employees face uncertainty regarding job security due to the company's financial challenges.
• Customers may be impacted by potential disruptions in the supply of PHEXXI and SOLOSEC.
• Suppliers and creditors face the risk of delayed or non-payment due to the company's financial difficulties.

Next Steps

• Evofem will continue to focus on top-line growth and explore opportunities for organic growth.
• Evofem will work to meet the conditions for the merger with Aditxt, including addressing the Notice of Event of Default.
• Evofem will seek to secure additional funding through various means.

Key Dates

Keywords

Evofem, Aditxt, Merger Agreement, PHEXXI, SOLOSEC, Financial Results, Going Concern, Amendment, Investment, Convertible Notes